What is Rasio?
Rasio Therapeutics, Inc. is a biopharmaceutical firm based in Maryland, specializing in the creation of innovative medicines through advanced computer-aided drug design technology. The company has established a partnership with SilcsBio, a recognized leader in computational drug discovery, to engineer small molecules targeting challenging disease indications. Rasio's initial strategic focus is on oncology, aiming to address areas with substantial unmet medical needs.
How much funding has Rasio raised?
Rasio has raised a total of $1.5M across 1 funding round:
Unspecified
$1.5M
Unspecified (2021): $1.5M with participation from Bluedot Bio
Key Investors in Rasio
Bluedot Bio
Bluedot Bio is an investor participating in the funding round, with its specific investment focus yet to be detailed.
What's next for Rasio?
With its recent major enterprise-level funding, Rasio Therapeutics is poised for accelerated growth and development. The company's strategic investment is expected to fuel the design and advancement of its oncology therapeutics pipeline. This capital infusion will likely enable Rasio to expand its research and development capabilities, potentially moving its novel drug candidates closer to clinical trials and further solidifying its position in the competitive biopharmaceutical landscape.
See full Rasio company page
